Abiopharma

🔍 Kirk Sigurd (Director)

Company: Assertio Holdings, Inc. (ASRT)

Report Date: 2026-06-16

Detailed Transactions and Holdings:

• Sold 12,017 shares of Common Stock (Direct)
  Date: 2026-06-16 | Code: U | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 7,913 shares of Stock Option (Right to Buy) at $17.1 per share (Derivative)
  Date: 2026-06-16 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 5,415 shares of Stock Option (Right to Buy) at $15.15 per share (Derivative)
  Date: 2026-06-16 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 5,415 shares of Stock Option (Right to Buy) at $9.2565 per share (Derivative)
  Date: 2026-06-16 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4

Footnotes:

• F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 13, 2026, by and among Assertio Holdings, Inc. (the "Issuer"), Zydus Worldwide DMCC ("Parent"), Zara Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser") and Zydus Pharmaceuticals (USA) Inc., pursuant to which Purchaser completed a tender offer (the "Offer") for all outstanding shares of common stock of the Issuer ("Company Common Stock") at a price of $23.50 per share in cash, without interest (the "Offer Price"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"), effective as of June 16, 2026 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right [continues to Footnote 2]
• F2: [continues from Footnote 1] to receive the Offer Price, less any applicable withholding taxes.
• F3: Pursuant to the Merger Agreement, each restricted stock unit of the Issuer (each, a "Company RSU") that was outstanding but unvested immediately prior to the Effective Time became fully vested as of immediately prior to the Effective Time and, at the Effective Time, each outstanding Company RSU was cancelled and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the Offer Price.
• F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock (each, a "Company Stock Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, with an exercise price per share less than the Offer Price, was cancelled at the Effective Time and converted into the right to receive a cash payment, less any applicable withholding taxes, equal to the product of (A) the excess of the Offer Price over the exercise price payable per share of Company Common Stock under such Company Stock Option, multiplied by (B) the total number of shares of Company Common Stock subject to such Company Stock Option. Each Company Stock Option with an exercise price per share equal to or greater than the Offer Price was cancelled at the Effective Time without any cash payment in respect thereof.